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Abstract
Background: Light chain (AL) amyloidosis is a rare disease characterized by misfolded amyloid protein deposits in
tissues and vital organs, and little is known about the burden of AL amyloidosis on health-related quality of life.
This study aimed to quantify the burden of AL amyloidosis in terms of health-related quality of life in a diverse,
community-based sample of AL amyloidosis patients.
Results: The SF-36v2® Health Survey (SF-36v2), a widely used generic measure of health-related quality of life
(using physical and mental summary scales and subscales assessing eight aspects of functioning and well-being),
was administered as an online survey of AL amyloidosis patients with AL amyloidosis (ClinicalTrials.gov, NCT02574676;
n = 341). Compared with adjusted general population sample norms, health-related quality of life of AL amyloidosis
patients was significantly worse across all SF-36v2 scales and summary measures based on analysis of variance (p < 0.05
for all). The largest decrement in AL amyloidosis patients was related to General Health (Δ = 9.7; p < 0.001). With the
exception of Bodily Pain and Mental Health, differences were also clinically meaningful based on established clinically
minimal important differences. The burden of AL amyloidosis overall and in key subgroups tended to be greater on
physical health than on mental health. Stratified analyses indicated additional burden among patients with recently
diagnosed disease and those with cardiac involvement than among their respective counterparts.
Conclusion: Understanding the burden of AL amyloidosis highlights the unmet need for treatment, helps physicians
identify ancillary treatments and services geared towards improving patients’ functioning, well-being, and overall
health-related quality of life. These findings also help to support the use of health-related quality of life end points
as important outcome measures in current and future treatment studies.
Trial registration: ClinicalTrials.gov, NCT02574676. Registered October 5, 2015.
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Background
Systemic amyloidoses are a group of rare diseases charac-
terized by abnormally folded protein (amyloid) deposits in
body tissue and organs. Accumulation of these insoluble
amyloid deposits can lead to organ toxicity, irreversible
organ damage, dysfunction, and death [1]. Amyloidosis
subtypes are defined by their fibril composition and pre-
cursor proteins. In amyloid light chain (AL) amyloidosis,
the amyloid deposits are created by immunoglobulin light
chain proteins produced by abnormal monoclonal plasma
cells [2]. The estimated incidence of AL amyloidosis is 8
to 12 cases per million person-years [3, 4].
AL amyloidosis is a complex disease with a variety
of clinical manifestations, nonspecific symptoms that
are associated with a wide range of diseases, and a
high-case fatality rate-factors that can contribute to
challenges in early diagnosis [5]. Symptoms and com-
plications depend on the number and types of organ
systems involved and the duration of time between
symptom onset and treatment. Although estimates
vary, approximately 70% of patients have cardiac
involvement and 68% have multiple organ involvement
at diagnosis [6]. Damage to multiple organs and car-
diac impairment are predictive of decreased survival
rates and poor disease outcomes; the most common
cause of death is cardiac complication [7].
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Prognosis for patients with AL amyloidosis is improved
by early diagnosis and treatment. No treatments have
been approved by either the United States Food and Drug
Administration (FDA) or the European Medicines Agency
(EMA), leaving substantial unmet need for patients. Typ-
ical treatments, which are adapted from regimens used to
treat multiple myeloma, include chemotherapy, stem cell
transplantation (SCT), and immunomodulatory drugs.
These treatments target plasma cells and aim to reduce
the production of amyloid-forming light chains. Existing
regimens can be associated with significant tolerability
problems, including treatment-emergent symptoms [8, 9].
Understanding the patient experience, including phys-
ical and mental aspects of health-related quality of life
(HRQoL), can help to characterize burden of disease.
Qualitative research indicates that patients with AL
amyloidosis experience substantial burden that can lead
to impairment in daily functioning [10, 11]. Further-
more, AL amyloidosis can lead to anxiety, frustration,
and depression as patients grapple with the gravity and
rarity of their condition [10, 12]. Although limited,
quantitative studies provide evidence of deficits in both
physical and mental aspects of HRQoL [13, 14].
Given the absence of a disease-specific measure of
HRQoL for AL amyloidosis and the disease heterogeneity,
a general health status measure, such as the SF-36v2
Health Survey® (SF-36v2), is well suited for assessing
HRQoL in this population [15]. The SF-36v2 is a widely
used generic measure of HRQoL and the most com-
mon patient-reported outcome end point in clinical
trials [16–18]. Generic measures of HRQoL allow for
comparisons with the general population and other
disease populations, which can provide context for rare
diseases [19, 20].
Studies examining the impact of AL amyloidosis on
HRQoL, particularly among patient subgroups, are scant.
Accordingly, this study used the SF-36v2 to compare the
HRQoL burden of AL amyloidosis patients and two key
subgroups hypothesized to have greater disease severity
with that observed in the US general population (GP).
Methods
Sample/study procedures
The study is a cross-sectional analysis of baseline data
(n = 341) taken from the AL Amyloidosis Patient
Health-Related Quality of Life Study (ClinicalTrials.gov;
NCT02574676), an online noninterventional, longitu-
dinal study of patients with AL amyloidosis. This study
was approved by the New England Institutional Review
Board. Recruitment took place between October and
December 2015, with scripted messages posted on pa-
tient advocacy group Web sites and social media sites
and in membership e-mails. These messages provided a
hyperlink to an electronic informed consent form and
screening questions. Potential participants were eligible
to participate if they were ≥18 years of age, received a
diagnosis of AL amyloidosis from a physician, and were
willing and able to complete four online surveys over
the course of 12 months. Those who met inclusion cri-
teria were automatically directed to the baseline survey.
Study measures
Several items capturing basic demographic, disease, and
treatment characteristics were used to describe the sample.
Dates of diagnosis and survey completion were used to
calculate the time since each patient received the AL amyl-
oidosis diagnosis. Specific organ involvement was mea-
sured with a six-item checklist of organs or systems
commonly affected by AL amyloidosis, including heart
(cardiac), kidney, liver, nervous system, and gastrointestinal
system. Responses to these items were summed to gener-
ate a composite measure of the total number of organs
affected. Hematologic response (HR), based on the assess-
ments of serum-free light chains, is often used as a meas-
ure of treatment efficacy for AL amyloidosis [21]. In this
study, a proxy measure of this clinical information was
developed by asking patients to describe their most recent
HR status in terms of the following: (1) no response to
treatment, (2) partial HR or partial remission, (3) complete
HR or complete remission, or (4) I do not know.
The SF-36v2 (with 4-week recall) was used to measure
general HRQoL burden in eight dimensions of func-
tional health and well-being: Physical Functioning (PF),
Role-Physical (RP; role limitations due to physical prob-
lems), Bodily Pain (BP), General Health Perceptions
(GH), Vitality (VT), Social Functioning (SF), Role-
Emotional (RE; role limitations due to emotional prob-
lems), and Mental Health (MH). Item responses were
used to calculate scale scores for each of the eight di-
mensions, and summary scores (Physical Component
Summary [PCS] and Mental Component Summary
[MCS]) were computed from weighted scores from the
eight scales. All scores were calculated using a scoring
algorithm that yields standardized T scores for a nation-
ally representative sample of US adults [15]. Higher SF-
36v2 scores represent better health. Previously reported
minimal clinically important differences (MCIDs) for
each of the eight scales, PCS, and MCS were used to in-
terpret whether statistically significant differences were
also clinically meaningful [15].
Two other survey items were used to describe burden
in terms of current disease status or severity: a global as-
sessment of functioning on a scale of 0 to 100 (higher
scores mean better functioning) and the Patient Global
Impression–Severity scale (PGI-S). The PGI-S was used
to assess the severity of AL amyloidosis in the past
month on a five-point scale (not severe at all, mild, mod-
erate, severe, very severe) [22].
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Statistical analyses
Demographics, disease characteristics, and HRQoL were
compared in stratified analyses of two clinically relevant
subgroups: diagnosed <12 months ago versus diagnosed
≥12 months ago; cardiac involvement versus no cardiac
involvement. Unadjusted differences between the sub-
groups were examined using chi-square and Wilcoxon-
Mann–Whitney tests, as appropriate.
SF-36v2 scores for all patients and the key clinical
subgroups were compared with those from the GP.
Normative data were drawn from the QualityMetric
2009 Norming Study (N = 4040), a cross-sectional on-
line study conducted between June and October 2009.
The methodology for the GP has been described [15].
Participants were recruited from the Knowledge Panel®,
a probability sample of US households [23], to complete
an online survey that included the SF-36v2.
Data from the GP were adjusted to the age and gender
distribution of the AL amyloidosis sample using separate
least squares multiple regression models for each SF-
36v2 scale and summary score. Analysis of variance
methods were used to test for significant differences be-
tween scores obtained from the AL amyloidosis sample
and the adjusted norms.
All analyses were performed using SAS version 9.2
(SAS Institute Inc, Cary, NC).
Results
Sample characteristics
Sample characteristics are reported in Table 1. The aver-
age age of the patients was 61 years. Slightly more
women (52.9%) than men (47.1%) participated. Most
patients were white (89.1%), well educated (61.2% had at
least a 4-year college degree), and married (82.1%). Ap-
proximately 43% of patients were diagnosed >1 year after
the onset of symptoms. Time since diagnosis varied from
1 month to 28 years (median, 3.5 years). Nearly 23% of
the sample reported a history of multiple myeloma.
There was a broad representation of affected organs; the
largest percentage of patients had cardiac (52.2%) and/or
kidney (62.8%) involvement. In approximately 46.0% of
patients, three or more organs were affected by AL
amyloidosis. At the time of data collection, most patients
who had received at least one treatment series had ex-
perienced some type of response to treatment (39.3%
partial HR, 43.6% complete HR).
Patient demographics did not differ significantly by
time since diagnosis or cardiac involvement (data not
shown). Patients diagnosed <12 months ago differed
from those who received their diagnoses ≥12 months
ago on several key aspects of disease and treatment
(Table 2). Given their shorter duration of disease,
greater proportions of patients diagnosed <12 months
ago reported not having started treatment or having
received only one treatment series to date. They were
also less likely to have undergone SCT and less likely to
have achieved complete HR than those with longer
disease duration. Patients with cardiac involvement did
not differ significantly from those without cardiac in-
volvement by HR or history of SCT.
The humanistic burden of AL amyloidosis
Compared with age- and gender-adjusted GP norms, pa-
tients with AL amyloidosis had worse HRQoL, as dem-
onstrated by their scores on all eight SF-36v2 scales and
summary scores (p < 0.05 for all) (Fig. 1). All differences,
with the exception of BP and MH, exceeded the estab-
lished MCIDs, indicating that these deficits are clinically
meaningful as well as statistically significant. The largest
differences were related predominantly to physical
health status. Compared with the GP, the largest observed
differences were related to GH (Δ = 9.7; Cohen’s d, −0.65;
p < 0.001) and RP (Δ = 7.1; Cohen’s d, −0.49; p < 0.001),
with corresponding decrements in PCS (Δ = 5.9; Cohen’s
d, −0.44; p < 0.001). Significant decrements were also seen
for scales assessing mental health status, such as SF
(Δ = 6.0; Cohen’s d, −0.40; p < 0.001) and VT (Δ = 5.8;
Cohen’s d, −0.39; p < 0 .001), and a corresponding
deficit was seen for the MCS (Δ = 3.7; Cohen’s d,
−0.25; p < 0.001).
Overall SF-36v2 scores and other HRQoL measures
are reported in Table 3. The average global assessment
of functioning score was 70.2 (SD, 23.7). Based on re-
sponses to the PGI-S, slightly more than one-third of all
patients described the severity of their condition as
moderate to very severe (34.0%).
The humanistic burden among patients with recently
diagnosed AL amyloidosis
Patients diagnosed <12 months earlier exhibited large
decrements in all eight SF-36v2 scale scores, PCS, and
MCS (p < 0.05 for all) compared with the GP (Fig. 2).
Consistent with patterns observed in the overall sam-
ple, the burden among recently diagnosed patients was
greater for physical health status than mental health sta-
tus. The greatest HRQoL decrement among these patients
was in RP (Δ = 12.3; Cohen’s d, −1.01; p < 0.001), with
other large decrements in GH (Δ = 10.2; Cohen’s d, −0.81;
p < 0.001) and SF (Δ = 10.8; Cohen’s d, −0.85; p < 0.001).
Deficits in HRQoL among AL amyloidosis patients
with recent diagnoses often exceeded those among pa-
tients diagnosed ≥12 months ago (Table 4). Patients
with recent diagnoses reported worse scores on PF, RP,
VT, SF, RE, MH, and MCS than did those diagnosed
≥12 months ago (p < 0.05 for all). Furthermore, all dif-
ferences exceeded the established MCIDs for these
scales/scores. There were no significant differences for
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BP, GH, and PCS, though both groups of patients were
severely impaired in these areas.
Responses to the global assessment of functioning
and the PGI-S reinforced the finding of added burden
among patients with recent diagnoses (Table 4). The
mean global assessment of functioning score was ap-
proximately 22% greater for those with diagnoses made
≥12 months ago than for those with more recent diag-
noses (72.2 vs 59.1, respectively; p < 0.05), indicating
better functioning among those whose disease was
diagnosed for a longer period of time. A greater pro-
portion of patients with recent diagnoses described the
severity of their disease as moderate to very severe
(55.7%) than did patients diagnosed ≥12 months ago
(30.0%) (p < 0.001).





Mean age, years (SD) 60.6 (10.2)
Range, years (median) 23–85 (61)






Education (n = 322)a
≤ High school diploma or GED® 26 8.1
Some college but no degree 50 15.5
A Associate’s degree or technical certificate 49 15.2
Bachelor’s degree 109 33.9
Graduate degree 88 27.3




Currently employed for pay 115 38.3







Mean time since diagnosis, years (SD) 4.5 (4.0)
Range (median) 1 month–28
years (3.5 years)
Time between onset of symptoms and diagnosis
Less than 6 months 96 28.2
Between 6 months and 1 year 97 28.4
Between 1 and 2 years 76 22.3
Between 2 and 3 years 31 9.1
More than 3 years 41 12.0





Five or more 145 42.9
Table 1 Demographic, Disease, and Treatment Characteristics of
Study Participants (Continued)
Organs/systems impactedb
Heart (cardiac) 178 52.2
Kidney 214 62.8
Liver 49 14.4
Nervous system 126 37.0
Gastrointestinal 148 43.4
Other 117 34.3
Number of organs involved
One 95 27.9
Two 89 26.1
Three or more 157 46.0
History of multiple myeloma 71 22.8






Five or more 89 26.1
Ever underwent stem cell transplantation 180 52.9
Most recent hematologic response status (n = 321)c
No response to treatment 20 6.2
Partial hematologic response or partial remission 126 39.3
Complete hematologic response or complete
remission
140 43.6
I do not know 35 10.9
GED, General Educational Development; SD, standard deviation
aFrequencies less than 341 are due to missing data; Percentages based on
available data
bMultiple response options allowed
cFrequencies and percentages are based on the 321 patients who received
at least one treatment series
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Table 2 Disease and Treatment Characteristics by Time since Diagnosis and Cardiac Involvement









n % n % P value n % n % P value
No. organs involved 0.047 <0.001
One 20 38.5 75 26.0 71 43.6 24 13.5
Two 16 30.8 73 25.3 42 25.8 47 26.4
Three or more 16 30.8 141 48.8 50 30.7 107 60.1
No. treatment series received 0.889
None 8 15.4 12 4.2 <0.001 12 7.4 8 4.5
One 16 30.8 54 18.7 32 19.6 38 21.3
Two 5 9.6 71 24.6 34 20.9 42 23.6
Three 4 7.7 57 19.7 29 17.8 32 18.0
Four 5 9.6 20 6.9 12 7.4 13 7.3
Five or more 14 26.9 75 26.0 44 27.0 45 25.3
Ever underwent stem cell transplantation (% yes) 5 9.8 175 60.6 <0.001 89 54.6 91 51.4 0.556
Most recent hematologic response statusa <0.008 0.135
No response to treatment 5 11.6 15 5.4 9 6.0 11 6.5
Partial hematologic response or partial remission 19 44.2 107 38.5 62 41.1 64 37.7
Complete hematologic response or complete remission 10 23.3 130 46.8 58 38.4 82 48.2
I do not know 9 20.9 26 9.4 22 14.6 13 7.7





























































Fig. 1 Mean SF-36v2 scores of patients with AL amyloidosis and of a general population. Error bars indicate 95% confidence intervals; GP adjusted
to the age and gender distribution of sample of AL amyloidosis patients; GP sample size varied by scale/score: PF = 4034; RP = 4027; BP = 4027;
GH = 4036; VT = 4028; SF = 4029; RE = 4026; MH = 4028; PCS = 4024 MCS = 4024. * GP > AL amyloidosis patients, p < 0.05. **GP > AL amyloidosis
patients, p < 0.01. †GP > AL amyloidosis patients, p < 0.001
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The humanistic burden among AL amyloidosis patients
with cardiac involvement
Compared with the GP, patients with cardiac involve-
ment also reported large decrements on all eight SF-
36v2 scales and summary scores (p < 0.05 for all) (Fig. 3).
With the exception of BP and MH, all differences
exceeded established MCIDs. Similar to the finding in
the overall sample, the largest deficits were for scales
that contribute to physical health status (ie, PF, RP, and
GH). Similarly, AL amyloidosis patients with cardiac in-
volvement had significantly lower PCS scores than the
adjusted GP (p < 0 .001).
Results indicate that AL amyloidosis with cardiac in-
volvement is associated with greater physical impairment
than with non-cardiac organ involvement (Table 4).
Mean SF-36v2 scores for patients with cardiac involve-
ment were significantly lower for patients without car-
diac involvement for three of the four physical scales
(PF, RP, and GH; p < 0.05 for all) and subsequently for
PCS (p < 0.001). No significant differences were observed
for MH scores or the MCS.
Responses on the PGI-S and global assessment of
functioning items differed by presence of cardiac in-
volvement (Table 4). Patients with cardiac involvement
were half as likely as those without cardiac involvement
to classify their condition as “not severe at all” (27.5% vs
51.5%, respectively). A significantly greater proportion of
Table 3 Health-related quality of life among AL Amyloidosis
patients (n = 341)
AL amyloidosis patients N = 341
Mean (SD)
SF-36v2 norm-based scalesa
Physical functioning (PF) 42.5 (10.6)
Role physical (RP) 40.5 (11.3)
Bodily pain (BP) 46.6 (10.6)
General health (GH) 39.3 (10.6)
Vitality (VT) 44.5 (11.1)
Social functioning (SF) 43.6 (11.5)
Role emotional (RE) 45.3 (12.3)
Mental health (MH) 49.1 (10.6)
SF-36v2 Summary Scores
Physical Component Summary (PCS) 40.7 (10.3)
Mental Component Summary (MCS) 47.9 (11.6)
Global assessment of functioning 70.2 (23.7)
Patient Global Impression–Severity Scale (PGI-S) n %




Very severe 12 3.5





























































Fig. 2 Mean SF-36v2 scores of patients with recently diagnosed AL amyloidosis and of a general population. Error bars indicate 95% confidence
intervals; GP adjusted to the age and gender distribution of sample of AL amyloidosis patients; GP sample size varied by scale/score: PF =
4034; RP = 4027; BP = 4027; GH = 4036; VT = 4028; SF = 4029; RE = 4026; MH = 4028; PCS = 4024, MCS = 4024. *GP > AL amyloidosis patients, p <
0.05. **GP > AL amyloidosis patients, p < 0.01.†GP > AL amyloidosis patients, p < 0.001
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patients with cardiac involvement than without it de-
scribed the severity of their disease as moderate to very
severe (43.2% vs 24.0%, respectively) (p < 0.001).
Discussion
These results indicate that AL amyloidosis patients have
broad HRQoL deficits relative to a general population.
Decrements in physical and mental functioning were
statistically significant and often exceeded thresholds for
clinically meaningful differences. The largest effects were
observed in aspects related to physical functioning and
general well-being. For instance, GH and RP were
among the greatest deficits observed overall and in each
key subgroup.
As expected, there was greater impairment in patients
with recent diagnoses and those with cardiac involve-
ment. Cardiac involvement in AL amyloidosis can lead
to complications such as cardiomyopathy and heart
failure. Although there are no other known studies that
report HRQoL specifically in AL amyloidosis patients
with cardiac involvement, our findings are congruent
with assessments in populations with non-amyloidosis
cardiomyopathy and heart failure [24].
This is the first study to characterize HRQoL in a
community-based sample of AL amyloidosis patients
and to further document HRQoL specifically in cardiac
AL amyloidosis patients. Previous HRQoL-related stud-
ies in AL amyloidosis used older versions of the SF-36,
relied on clinic-based samples, and predated many of
the newer drugs used to treat AL amyloidosis [13, 14].
By partnering with patient advocacy groups, we were
able to overcome some of the challenges of sample ac-
crual and data collection often experienced in studies
of rare diseases. Since recruitment occurred outside of
the clinic setting, we were able to obtain a diverse sam-
ple of patients that included patients with recent diag-
noses and long-term survivors. Rather than having
patients complete a time-intensive survey in a clinic
setting, the centralized, online mode of data collection
used in this study allowed patients to complete the
survey on their own time and from any location, which
facilitated participation.
Despite the benefits of our recruitment and data
collection strategies, several limitations are worth noting.
All measures in this study relied on self-report. Al-
though some measures were meant to be subjective (ie,
Table 4 Health-Related Quality of Life by Time since Diagnosis and Cardiac Involvement









Mean (SD) Mean (SD) P value Mean (SD) Mean (SD) P value
SF-36v2 norm-based scalesa
Physical functioning (PF) 38.7 (12.4) 43.2 (10.2) 0.015 44.5 (10.9) 40.7 (10.0) <0.001
Role physical (RP) 35.6 (12.7) 41.4 (10.9) 0.001 41.8 (11.7) 39.3 (10.9) 0.043
Bodily pain (BP) 44.0 (11.6) 47.0 (10.4) 0.099 47.2 (10.8) 46.1 (10.4) 0.257
General health (GH) 38.8 (11.7) 39.4 (10.3) 0.827 40.9 (10.5) 37.7 (10.4) 0.005
Vitality (VT) 40.9 (12.1) 45.1 (10.8) 0.027 44.9 (11.5) 44.1 (10.7) 0.530
Social functioning (SF) 38.7 (13.3) 44.5 (10.9) 0.003 43.8 (11.7) 43.5 (11.3) 0.786
Role emotional (RE) 41.0 (15.1) 46.1 (11.5) 0.038 45.3 (12.0) 45.3 (12.5) 0.900
Mental health (MH) 44.8 (13.0) 49.8 (10.0) 0.012 48.9 (10.8) 49.2 (10.5) 0.803
SF-36v2 Summary Scores
P Physical Component Summary (PCS) 38.2 (11.9) 41.2 (9.9) 0.064 42.7 (10.6) 38.9 (9.6) <0.001
Mental Component Summary (MCS) 43.5 (13.5) 48.7 (11.1) 0.012 47.2 (11.9) 48.5 (11.4) 0.348
Global assessment of functioning 59.1 (31.2) 72.2 (21.6) 0.015 73.1 (23.5) 67.5 (23.7) 0.013
Patient Global Impression–Severity Scale (PGI-S) n % n % n % n %
<0.001 <0.001
Not severe at all 11 21.2 122 42.2 84 51.5 49 27.5
Mild 12 23.1 80 27.7 40 24.5 52 29.2
Moderate 15 28.8 66 22.8 26 16.0 55 30.9
Severe 9 17.3 14 4.8 8 4.9 15 8.4
Very severe 5 9.6 7 2.4 5 3.1 7 3.9
aSF-36v2, SF-36v2 Health Survey
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the PGI-S), other measures of disease severity were
meant to be proxies for objective measures, such as HR
or cardiac involvement. These proxy measures may have
been affected by measurement error. HR, in particular,
relies on patients’ recall and understanding of infor-
mation relayed to them by their clinicians. A notable
proportion of the sample (11%) acknowledged their
uncertainty of their current HR status by endorsing
the ‘I do not know’ category.
Our sample may represent a healthier subset of AL
amyloidosis patients. First, despite advances in the
treatment of patients with AL amyloidosis, the preva-
lence of sudden death within 90 days of diagnosis re-
mains around 25–30%, whereas patients who survive
>12 months have a better prognosis [25–27]. Here, 85%
of patients in this sample received their diagnoses
≥12 months ago, and the median time since diagnosis
within this sample was 3.5 years. This is typical of
cross-sectional studies in which short-term survivors
are often underrepresented among prevalent cases [28].
Second, only the healthiest AL amyloidosis patients
(<20% of all patients) are typically eligible to undergo
SCT [29], but the lifetime prevalence of SCT in this
sample was 53%. Finally, 41% of the sample reported
current complete remission or HR, indicating that a
substantial proportion of this sample responded favor-
ably to treatment.
Despite the likelihood that this sample might have
been disproportionately healthier than the broader
population of AL amyloidosis patients, the demographic
characteristics of our study population mirror those previ-
ously described in the literature, including those of
patients with newly diagnosed AL amyloidosis and long-
term survivors with a range of organ involvement [3, 14].
However, given the likelihood that our sample represented
healthier patients, it is probable that the HRQoL in
patients with AL amyloidosis is actually lower.
These findings may help clinicians understand how
their patients are impacted by AL amyloidosis. Under-
standing the burden of AL amyloidosis can help phy-
sicians identify ancillary treatments and services that
may ease patients’ disease burden and ultimately
improve their HRQoL. Subsequently, this may im-
prove the doctor-patient relationship through a
patient-centered approach.
Furthermore, these findings may interest regulatory
groups, such as the FDA and the EMA. FDA’s Guidance
for Industry in Rare Diseases specifically notes that rare
diseases are highly diverse and that, due to the small
number of patients affected and the clinical expertise
dispersed among a small number of treatment centers,
the natural history of rare diseases is often poorly de-
scribed, as are “patient reports of function and feeling”









































AL amyloidosis patients with cardiac involvement (n=178)
** 
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Fig. 3 Mean SF-36v2 scores of patients with AL amyloidosis and cardiac involvement and of a general population. Error bars indicate 95%
confidence intervals; GP adjusted to the age and gender distribution of sample of AL amyloidosis patients; GP sample size varied by scale/
score: PF = 4034; RP = 4027; BP = 4027; GH = 4036; VT = 4028; SF = 4029; RE = 4026; MH = 4028; PCS = 4024, MCS = 4024. *GP > AL amyloidosis
patients, p < 0.05. **GP > AL amyloidosis patients, p < 0.001
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conduct observational studies to facilitate understanding
of the population and unmet need, to define the disease
population and subtypes, and to design appropriate
clinical trials with suitable outcome measures that are
sensitive to change in disease status and that are reliable
and valid for the intended use.
Conclusions
Overall these data demonstrated significant deficits in
HRQoL among AL amyloidosis patients and an add-
itional burden among clinically relevant subgroups of
patients. Further, this study indicates that the SF-36v2 is
sensitive to variations in HRQoL across groups known
to differ in disease severity. The study is continuing to
collect data to evaluate the change in HRQoL over time
and in other subgroups. Given the importance of provid-
ing patient-centered care and including the patient’s
voice in research, these findings are relevant to a variety
of stakeholders, among them physicians, patients, payors,
and regulatory groups.
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